Tuesday, July 21, 2026
🇺🇸 FDA

pharma · Nonalcoholic Steatohepatitis (NASH) · Amyotrophic Lateral Sclerosis · CORT

CORCEPT THERAPEUTICS

CORCEPT THERAPEUTICS INC

CORCEPT THERAPEUTICS patent portfolio — 33 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
101 Redwood Shores Pkwy, Redwood City, California 94065, US HQ
1998 Founded
756 Employees
Public company Type
CORT · NYSE Ticker
Company details
Status
Public
HQ
101 Redwood Shores Pkwy, Redwood City, California 94065, US
Founded
1998
Employees
756
Programs
1
Drugs
18
Patents
33
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

CORCEPT THERAPEUTICS patents

33 pharmaceutical patents indexed for CORCEPT THERAPEUTICS. 0 expire within 24 months.

CORCEPT THERAPEUTICS has 33 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

33 patents

Patent portfolio

  1. US 12152028

    Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12097210

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12097192

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11969435

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11944617

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11925626

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11684612

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11590113

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11576907

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11464764

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11285145

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11173165

    Optimizing mifepristone levels for Cushing's patients

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11058670

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10842800

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10842801

    Optimizing mifepristone absorption

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10780097

    Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10660904

    Optimizing mifepristone levels for cushing's patients

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10500216

    Optimizing mifepristone absorption

    Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10495650

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10456392

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10314850

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10231983

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10195214

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10166243

    Optimizing mifepristone levels for cushing'S patients

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10166242

    Optimizing mifepristone levels for Cushing's patients

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10151763

    Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10006924

    Method for differentially diagnosing ACTH-dependent cushing's syndrome

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9943526

    Optimizing mifepristone levels for cushing's patients

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9829495

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9273047

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8921348

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8859774

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8598149

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does CORCEPT THERAPEUTICS have?

33 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do CORCEPT THERAPEUTICS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.